Suppr超能文献

关于人类原发性甲状腺功能减退症中生长激素(GH)可释放池耗竭的反证:使用生长激素释放激素、吡啶斯的明和精氨酸的研究

Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.

作者信息

Valcavi R, Valente F, Dieguez C, Zini M, Procopio M, Portioli I, Ghigo E

机构信息

Second Division of Internal Medicine, Arcispedale S. Maria Nuova, Reggio Emilia, Italy.

出版信息

J Clin Endocrinol Metab. 1993 Sep;77(3):616-20. doi: 10.1210/jcem.77.3.8103770.

Abstract

We investigated whether the impaired GH secretion of hypothyroid patients could be due to an increase in hypothalamic somatostatinergic tone. Twenty-four patients with primary hypothyroidism [20 females and 4 males; mean age (+/- SE), 47.5 +/- 2.7 yr] and 20 normal subjects (17 females and 3 males; age, 47.6 +/- 3.0 yr) were studied. In the first group of 12 hypothyroid patients, administration of pyridostigmine, a cholinergic agonist drug (120 mg, orally, at -60 min), notably increased GH responses to GH-releasing hormone (GHRH; 1 microgram/kg, iv, at 0 min; peak GH levels for pyridostigmine plus GHRH vs. placebo plus GHRH, 16.6 +/- 4.9 vs. 6.0 +/- 1.8 micrograms/L; P < 0.01). The GH responses to pyridostigmine plus GHRH, however, were considerably lower than those in 10 normal subjects (peak GH levels, 53.0 +/- 3.5 micrograms/L; P < 0.001). In the second group of 12 hypothyroid patients, arginine infusion (30 g, iv, from 0-30 min) markedly increased the GH responses induced by GHRH administration (1 microgram/kg, iv, at 0 min; peak GH levels for arginine plus GHRH vs. placebo plus GHRH, 30.6 +/- 4.7 vs. 5.3 +/- 1.0 micrograms/L; P < 0.001). However, GH release after GHRH plus arginine was greater in 10 normal subjects than in the hypothyroid patients (peak GH levels, 50.9 +/- 5.3 micrograms/L; P < 0.001). Pyridostigmine and arginine inhibit hypothalamic somatostatin tone. The stimulatory effect of both agents on GHRH-induced GH release indicates that reduced GH secretion in hypothyroidism can be reversed to a considerable extent by inhibiting hypothalamic somatostatinergic tone. The relatively greater potency of arginine compared to pyridostigmine suggests that hypothyroid patients may have an impairment of the cholinergic pathways. Furthermore, these data show that hypothyroid patients have a somatotrope secretory capacity much greater than previously thought.

摘要

我们研究了甲状腺功能减退患者生长激素(GH)分泌受损是否可能是由于下丘脑生长抑素能张力增加所致。对24例原发性甲状腺功能减退患者[20例女性和4例男性;平均年龄(±标准误),47.5±2.7岁]和20名正常受试者(17例女性和3例男性;年龄,47.6±3.0岁)进行了研究。在第一组12例甲状腺功能减退患者中,给予胆碱能激动剂药物吡啶斯的明(120mg,口服,在-60分钟),显著增加了GH对生长激素释放激素(GHRH;1μg/kg,静脉注射,在0分钟)的反应(吡啶斯的明加GHRH组与安慰剂加GHRH组的GH峰值水平,分别为16.6±4.9与6.0±1.8μg/L;P<0.01)。然而,吡啶斯的明加GHRH后的GH反应明显低于10名正常受试者(GH峰值水平,53.0±3.5μg/L;P<0.001)。在第二组12例甲状腺功能减退患者中,精氨酸输注(30g,静脉注射,从0至30分钟)显著增加了GHRH给药诱导的GH反应(1μg/kg,静脉注射,在0分钟;精氨酸加GHRH组与安慰剂加GHRH组的GH峰值水平,分别为30.6±4.7与5.3±1.0μg/L;P<0.001)。然而,GHRH加精氨酸后的GH释放在10名正常受试者中比在甲状腺功能减退患者中更大(GH峰值水平,50.9±5.3μg/L;P<0.001)。吡啶斯的明和精氨酸可抑制下丘脑生长抑素张力。两种药物对GHRH诱导的GH释放的刺激作用表明,通过抑制下丘脑生长抑素能张力,甲状腺功能减退症中降低的GH分泌可在很大程度上得到逆转。与吡啶斯的明相比,精氨酸的效力相对更强,这表明甲状腺功能减退患者可能存在胆碱能途径的损害。此外,这些数据表明,甲状腺功能减退患者的生长激素分泌细胞分泌能力比以前认为的要大得多。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验